Products
Avizakimab Biosimilar Monoclonal Antibody (IL-21) for Research
Pre-Made Avizakimab biosimilar, Whole mAb, Anti-IL21 Antibody: Anti-CVID11/IL-21/Za11 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Avizakimab (formerly BOS 161721) is a fully human anti-interleukin 21 monoclonal antibody, being developed by Boston Pharmaceuticals, for treatment of autoimmune disorders including systemic lupus erythematosus.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-041-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Avizakimab biosimilar, Whole mAb, Anti-IL21 Antibody: Anti-CVID11/IL-21/Za11 therapeutic antibody |
| INN Name | Avizakimab |
| Target | IL21 |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | MedImmune;Boston Pharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Systemic lupus erythematosus |
| Conditions Discontinued | Autoimmune disorders |
| Development Tech | na |
About target - IL21
1. Protein Interleukin-21
2. Gene IL21
3. Organism Homo sapiens (Human)
Function
Cytokine with immunoregulatory activity. May promote the transition between innate and adaptive immunity. Induces the production of IgG1 and IgG3 in B-cells (By similarity).
Implicated in the generation and maintenance of T follicular helper (Tfh) cells and the formation of germinal-centers. Together with IL6, control the early generation of Tfh cells and are critical for an effective antibody response to acute viral infection (By similarity).
May play a role in proliferation and maturation of natural killer (NK) cells in synergy with IL15. May regulate proliferation of mature B- and T-cells in response to activating stimuli. In synergy with IL15 and IL18 stimulates interferon gamma production in T-cells and NK cells (PubMed:11081504, PubMed:15178704).
During T-cell mediated immune response may inhibit dendritic cells (DC) activation and maturation (By similarity).
Caution
It is uncertain whether Met-1 or Met-8 is the initiator.
